Cardior Pharmaceuticals GmbH news
Hanover, Germany, March 2, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry Ticho, MD, PhD, will provide Cardior with important scientific, medical and development
Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B financing round. The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and Hig
Hanover, Germany, June 24, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of the American College of Cardiology. The data confirm that the inhibition of the naturally occurring
Hanover, Germany, March 29, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Hanover, Germany, February 9, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from independent experts in the European Heart Journal Volume 42, Issue 3, January 14, 2021, an issue foc